A pipeline of powerful possibilities.

Our dynamic portfolio of virology assets includes a pipeline focused on curing HBV and treating coronavirus infections. Today, we have several active preclinical studies and clinical trials in these therapeutic areas, including approaches combining different mechanisms of action to achieve our therapeutic goals.

Arbutus Powerful Pipeline

Lead Optimization

IND Enabling

Phase 1

Phase 2

Phase 3



RNAi Therapeutic AB-729

AB-729-001 single-ascending dose / multiple-ascending dose

AB-729-201 Combo trial (AB-729 + Peg-IFNa-2a + NA)

AB-729-202 Combo trial (AB-729 + vaccine + NA )

RNA destabilizer (oral) AB-161

PD-L1 Inhibitor (oral) AB-101


Mpro inhibitor (oral) AB-343

nsp12 polymerase inhibitor (oral)

All Arbutus clinical trials are conducted in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice

Suppress Reduce Boost


Learn about our three-pronged Suppress, Reduce, Boost approach to HBV.

Discover our HBV assets

Pan Coronavirus Treatment


Learn more about how we are innovating in pan-coronavirus treatment.

Discover our coronavirus assets